Giles Campion
Keine laufenden Positionen mehr
Vermögen: 79 200 $ am 31.07.2023
Profil
Giles Campion is the founder of PepGen Inc. (founded in 2018).
He was the Executive Director & Chief Medical Officer at Silence Therapeutics Plc from 2020 to 2023.
He was the Group Vice President-Neuromuscular Franchise at BioMarin Pharmaceutical, Inc. from 2015 to 2016.
He was the Chief Medical Officer, SVP-Research & Development at Prosensa Holding NV from 2009 to 2016.
He was the Chief Medical Officer at Albumedix Ltd.
from 2017 to 2018.
Dr. Campion received his undergraduate and doctorate degrees from the University of Bristol.
Dr. Campion is also the founder of PepGen Ltd...
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
SILENCE THERAPEUTICS PLC
0,08% | 31.12.2023 | 90 000 ( 0,08% ) | 79 200 $ | 31.07.2023 |
Ehemalige bekannte Positionen von Giles Campion
Unternehmen | Position | Ende |
---|---|---|
SILENCE THERAPEUTICS PLC | Chief Tech/Sci/R&D Officer | 01.04.2023 |
Albumedix Ltd.
Albumedix Ltd. BiotechnologyHealth Technology Part of Sartorius AG, Albumedix Ltd. is a British science-driven company and recognized leader of albumin-enabled solutions. The private company, based in Nottingham, UK, was founded in 1984 with a mission to empower excellence. Albumedix has supported its life-science partners in delivering safe doses of clinical and marketed therapeutics. The company's solutions include the world's only USP-NF compliant recombinant human albumin, client-centric development and compliance services, and drug-enhancing technologies. By challenging the status quo and striving for more, Albumedix enables the development and commercialization of advanced therapies and next-generation biopharmaceuticals. Albumedix is the world leader in recombinant human albumin and has developed a portfolio of products known as Recombumin®. Founded in 1973, the CEO of Albumedix is Jonas S. Moller. The company was acquired by Sartorius Stedim Biotech SA on September 30, 2022, for $500.47 million. | Chief Tech/Sci/R&D Officer | 01.07.2018 |
BIOMARIN PHARMACEUTICAL INC. | Corporate Officer/Principal | 01.03.2016 |
PROSENSA HOLDING NV | Chief Tech/Sci/R&D Officer | 01.01.2016 |
PEPGEN INC. | Founder | - |
Ausbildung von Giles Campion
University of Bristol | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
BIOMARIN PHARMACEUTICAL INC. | Health Technology |
SILENCE THERAPEUTICS PLC | Commercial Services |
PEPGEN INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Prosensa Holding NV
Prosensa Holding NV BiotechnologyHealth Technology Prosensa Holding NV engages in the development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company focuses on rare neuromuscular and neurodegenerative disorders, Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. It has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. The company was founded in 2002 and is headquartered in Leiden, the Netherlands. | Health Technology |
Pepgen Ltd.
Pepgen Ltd. Packaged SoftwareTechnology Services Pepgen Ltd. engages in research and experimental development on biotechnology. The company was founded on January 25, 2018 and is headquartered in Oxford, the United Kingdom. | Technology Services |
Albumedix Ltd.
Albumedix Ltd. BiotechnologyHealth Technology Part of Sartorius AG, Albumedix Ltd. is a British science-driven company and recognized leader of albumin-enabled solutions. The private company, based in Nottingham, UK, was founded in 1984 with a mission to empower excellence. Albumedix has supported its life-science partners in delivering safe doses of clinical and marketed therapeutics. The company's solutions include the world's only USP-NF compliant recombinant human albumin, client-centric development and compliance services, and drug-enhancing technologies. By challenging the status quo and striving for more, Albumedix enables the development and commercialization of advanced therapies and next-generation biopharmaceuticals. Albumedix is the world leader in recombinant human albumin and has developed a portfolio of products known as Recombumin®. Founded in 1973, the CEO of Albumedix is Jonas S. Moller. The company was acquired by Sartorius Stedim Biotech SA on September 30, 2022, for $500.47 million. | Health Technology |